Takeda as a World-Class Partner
International strategic products
Takeda's products, including the four international strategic products[*], which Takeda created through proprietary research efforts, have gained high repute throughout the world. They are sold today in 90 countries, and their contribution to medical service providers as well as patients and their families is reflected by the increase in sales.
[*] Leuplin (generic name: Leuprorelin acetate), a treatment for prostate cancer and endometriosis; Takepron/Prevacid (generic name: Lansoprazole), a treatment for peptic ulcer; Blopress (generic name: Candesartan cilexetil), an anti-hypertensive agent; and Actos (generic name: pioglitazone hydrochloride), an antidiabetic agent.
In June 2010, it launched Nesina (alogliptin) for treatment of type 2 diabetes in Japan. Nesina is a dipeptidyl peptidase-IV (DPP-4) inhibitor to be administered orally once daily. We aim to obtain approval and launch it worldwide.
Presence in Japan and in the world
Takeda is Japan's largest pharmaceutical company, and one of the major global pharmaceutical companies.
Its sales bases are not limited to those in Japan. In the US, TPNA, a 100% US subsidiary, is in charge of Takeda’s sales activities and has established sales subsidiaries in Canada, Mexico, and Brazil. In the EU, TPEU (located in the United Kingdom) overalls the business activities in 15 countries (Germany, France, Italy, the United Kingdom, Spain, Portugal, Switzerland, Austria, Ireland, Sweden, Norway, Denmark, Belgium, Luxemburg, and Turkey). For the Asian regions in exception of Japan, TPAsia (located in Singapore) promotes Takeda’s sales through the activities of the sales subsidiaries in China, Taiwan, Thailand, the Philippines, and Indonesia.
Global research and development
Research and development bases have spread to 4 regions: Japan, the United States, Europe, and Asia. At seven research centers, i.e., Osaka and Tsukuba in Japan, San Diego, San Francisco and Boston in the US, Cambridge in the UK, and in Singapore, Takeda is endeavoring to create epoch-making new drugs that will follow its four international strategic products.
Takeda also has six development centers in Osaka and Tokyo in Japan, Chicago and Boston in the US, and London in the UK and in Singapore.